Home›Trial›NCT06054113

🔬NCT06054113Phase 2ACTIVE NOT RECRUITING

Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

Study Summary

The primary objective of this study is to evaluate the efficacy of blinatumomab.

Conditions

B Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia

Interventions / Drugs

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment18 participants

Primary Completion—

Lead SponsorAmgen

Data Retrieved2026-04-13 18:29:34.157411+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.